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Has the PROPHECY of AR-V7
Been Fulfilled?
TO THE EDITOR:
There is an unmet clinical need for predictive bio-
markers in metastatic castration-resistant prostate
cancer (mCRPC) resulting in unnecessary adverse
effects and costs. Conversely, there are several prog-
nostic biomarkers, such as circulating tumor cell (CTC)
counts, lactate dehydrogenase, and prostate-specific
antigen concentrations that have limited clinical utility
for guiding treatment selection. Armstrong et al1 re-
cently published the first data from the PROPHECY
trial (ClinicalTrials.gov identifier: NCT02269982; Pro-
spective Circulating Prostate Cancer Predictors in
Higher Risk mCRPC Study), a multicenter cohort study
that collected liquid biopsies with the primary goal of
validating the prognostic value of the androgen receptor
splice variant 7 (AR-V7) in men with mCRPC treated
with AR signaling inhibitors (either abiraterone or
enzalutamide). We applaud the authors for their great
effort to perform a validation trial. However, we have
concerns about their claims and statements regarding
how the analysis was performed, the selected patient
cohort, and the lack of prospective randomized clinical
trials (RCTs) supporting the treatment-predictive ca-
pability of AR-V7.
The PROPHECY trial report discusses two different
CTC-dependent assays for detecting AR-V7: the
Johns Hopkins University (JHC, Baltimore, MD)
modified-AdnaTest CTC AR-V7 mRNA assay and the
Epic Sciences (Epic; San Diego, CA) CTC nuclear-
specific AR-V7 protein assay. The number of CTCs
detected in 7.5 mL of blood, assessed by the
CELLSEARCH system (Menarini Silicon Biosystems;
Bryn Athyn, PA) is a highly prognostic continuous
variable.2 Although we understand that CTCs were
incorporated as the FDA-cleared dichotomous var-
iable with a cutoff of five CTCs, this limits the vari-
ance explained by the CTC counts. An additional
analysis using CELLSEARCH CTCs as a continuous
variable would be of great interest to the community
to fully understand whether AR-V7 harbors in-
dependent prognostic information or if simpler and
more widely accessible CELLSEARCH CTC enu-
meration could instead be applied for patient
prognostication. In addition, other prognostic vari-
ables were not individually assessed in the multi-
variable analysis; instead, the Halabi risk score was
used. The Halabi risk score was calibrated to predict
overall survival for patients receiving first-line che-
motherapy.3 A supplementary analysis would have
been of interest in which the prognostic variables
behind the Halabi score were applied directly in
a multivariable analysis to infer potential correlations
and interaction effects.
Furthermore, the patients included in the PROPH-
ECY trial were preselected to have two or more poor-
prognosis clinical factors, with half the cohort having
six or more. Importantly, 36% of patients received
previous treatment with an AR signaling inhibitor,
which is a known poor-prognosis factor in the context
of enzalutamide or abiraterone, and it increases the
likelihood of detectable treatment-induced expres-
sion of splice variants, including AR-V7.4 In addition,
PROPHECY patients with CTCs but without detect-
able AR-V7 expression did not progress faster than
CTC-negative patients, regardless of whether the
AdnaTest CTC AR-V7 mRNA assay or the CTC
nuclear-specific AR-V7 protein assay was used. This
result was unexpected because an increased tumor
burden in itself is strongly associated with progression-
free survival, regardless of treatment.5 Consequently,
these data are relevant only for preselected poor-
prognosis patients and cannot be extrapolated to an
all-comer setting.
Finally, the PROPHECY trial was designed to vali-
date the prognostic value of AR-V7. However, in
their discussion, the authors speculate that AR-V7 is
now ready to be applied as a predictive biomarker
for stratification of patients with mCRPC to either
taxanes or AR signaling inhibitors on the basis of
their previous work.6,7 However, the studies re-
ported in those articles did not prospectively ran-
domly assign patients on the basis of their AR-V7
status and were themselves controversial.8 Until
formally tested in an RCT, it is not known whether
the response rate of patients with AR-V7 is higher
with taxanes compared with AR signaling inhibitors.
Because the authors of the PROPHECY trial are
distinguished leaders in their field, their opinions
have considerable impact, and we are concerned
that the general conclusion resulting from their
study has been that AR-V7 is now ready for prime
time as a predictive biomarker.9
Going forward, we encourage the authors of the
PROPHECY trial to conduct an RCT to provide
conclusive evidence regarding whether AR-V7 can
be applied as a predictive biomarker or not. Since the
initial association of AR-V7 with AR signaling in-
hibitors in 2014, new knowledge has emerged. We
now know that TP53 mutation carriers respond
poorly4,10 and that the AR locus is hosting a plethora of
genomic alterations and noncanonical transcripts.4
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Comprehensive liquid biopsy profiling, beyond any single
biomarker, is therefore going to be needed to improve
stratification of patients with mCRPC. To address this es-
sential and unmet need, several prospective multiarm
clinical trials incorporating liquid biopsy profiling such as
the IND.234 (ClinicalTrials.gov identifier: NCT03385655;
Prostate Cancer Biomarker Enrichment and Treatment
Selection) and ProBio (ClinicalTrials.gov identifier:
NCT03903835; ProBio: A Biomarker Driven Study in Pa-
tients With Metastatic Castrate Resistant Prostate Cancer)
have been initiated that will eventually result in the iden-
tification of single biomarkers or biomarker signatures (eg,
DNA repair deficiency) that are predictive for personalized
treatment selection.
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